NYSE · Diagnostics & Research · USD
Agilent Technologies, Inc. (A) Stock Analysis
Agilent Technologies, Inc. (A) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
A Key Statistics
As of Oct 21, 2026Trading
- Open
- $170.73
- Previous Close
- $173.01
- Day's Range
- 171.23–178.21
- 52-Week Range
- 108.35–178.21
- Volume
- 2.13M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.21
Valuation
- Market Cap
- $50.12B
- P/E Ratio
- 35.06
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 26.34
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 1.43
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 6.80
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 5.07
Financials (FY)
- Revenue (FY)
- $6.95B+6.73%
- Net Income (FY)
- $1.30B+1.09%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 19.53%
- Shares Outstanding
- 281.97M
- 1-Year Return
- +22.93%
Dividend and dates
- Dividend
- $1.02+0.59%
- Ex-Dividend Date
- October 6, 2026
- Earnings Date
- November 25, 2026estimated
- Avg Volume
- 2.23M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, A closed at $177.75, +22.93% over 1 year.
Agilent Technologies, Inc. (A) has a market capitalization of $50.12B.
In fiscal 2025, A reported revenue of $6.95B.
A Stock Return by Calendar Year
Agilent Technologies, Inc. (A) 10-year return: what $10,000 became
- 1 year
- $10,000 $12,293
- +22.93%
- 5 years
- $10,000 $11,738
- +17.38%
- 10 years
- $10,000 $42,149
- +321.49%
If you had invested $10,000 in Agilent Technologies, Inc. (A) 10 years ago, at the close on October 21, 2016, it would have been worth $42,149 at the close on October 21, 2026: +321.49% in total, +15.47% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +31.61% |
| 2025 | +1.92% |
| 2024 | −2.70% |
| 2023 | −6.42% |
| 2022 | −5.52% |
| 2021 | +35.51% |
| 2020 | +39.79% |
| 2019 | +27.54% |
| 2018 | +1.67% |
| 2017 | +48.32% |
| 2016 (partial year) | −3.16% |
As of October 21, 2026.
A Revenue and Earnings by Fiscal Year
FY ends October| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $6.95B | $1.30B | 18.8% |
| 2024 | $6.51B | $1.29B | 19.8% |
| 2023 | $6.83B | $1.24B | 18.1% |
| 2022 | $6.85B | $1.25B | 18.3% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $6.95B | $3.64B | $1.48B | $1.30B | 18.8% |
| 2024 | $6.51B | $3.54B | $1.49B | $1.29B | 19.8% |
| 2023 | $6.83B | $3.47B | $1.35B | $1.24B | 18.1% |
| 2022 | $6.85B | $3.72B | $1.62B | $1.25B | 18.3% |
Annual figures as reported, in the company's reporting currency. As of October 31, 2025.
A Dividend History
Dividends per share, 2025 · 3 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $1.02 | 4 | — |
| 2025 | $0.74 | 3 | −22.2% |
| 2024 | $0.96 | 4 | +4.9% |
| 2023 | $0.91 | 4 | −14.5% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $1.02 | 4 | — |
| 2025 | $0.74 | 3 | −22.2% |
| 2024 | $0.96 | 4 | +4.9% |
| 2023 | $0.91 | 4 | −14.5% |
| 2022 | $1.07 | 5 | +37.2% |
| 2021 | $0.78 | 4 | +43.7% |
| 2020 | $0.54 | 3 | −19.6% |
| 2019 | $0.67 | 4 | +10.0% |
| 2018 | $0.61 | 4 | +12.1% |
| 2017 | $0.55 | 4 | +312.9% |
| 2016 | $0.13 | 1 | — |
Most recent payment: $0.26 per share, ex-dividend October 6, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
A Valuation vs Diagnostics & Research Median
Median of 45 stocks| Metric | A | Diagnostics & Research median | vs median |
|---|---|---|---|
| P/E | 35.06 | 37.59 | 7% below |
| P/S ratio | 6.80 | 5.23 | 30% above |
| Profit margin | 19.53% | −0.93% | 20.5 pts above |
Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Bioconjugation Market Report 2026: Global Size, Share, Trends and 2030 Forecast | Capitalize on Targeted Therapeutics | Thermo Fisher, Merck, Danaher, Lonza, and Agilent Lead the Industry
YahooAgilent Technologies (NYSE:A) Stands Out as a Quality Stock on Strong Returns and Cash Flow
ChartMill$1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
BenzingaAgilent acquires Proscia in deal worth up to $270m
medicaldevice-network.comWhy Agilent Is Spending up to $270 Million on an AI Pathology Specialist
BenzingaGlobal Metabolomics Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.3% CAGR as Thermo Fisher, Bruker, Agilent, and Metabolon Accelerate AI Diagnostics
Yahoo
All 20 articles ↓Show fewer ↑
Agilent to buy Proscia for $240M
MedTech DiveAgilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
YahooTD Cowen Maintains Buy on Agilent Technologies, Raises Price Target to $196
BenzingaMorgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $190
BenzingaGlobal Chromosomal Microarray Reflex Testing Market Report 2026-2030 | Capitalize on 9.1% CAGR as Thermo Fisher, LabCorp, Illumina, Agilent, and Natera Scale Precision Genomics
YahooIs Agilent Technologies (A) Outperforming Other Medical Stocks This Year?
YahooIs Agilent Technologies (A) Cheap Enough To Justify Its Cash Flow?
YahooBarclays Maintains Overweight on Agilent Technologies, Raises Price Target to $195
Benzinga$1000 Invested In Agilent Technologies 15 Years Ago Would Be Worth This Much Today
BenzingaAgilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
YahooAgilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
YahooAgilent Technologies (A) Tests Valuation On Exchange Offer And Recurring Revenue Story
YahooAgilent (A) Up 9.6% Since Last Earnings Report: Can It Continue?
YahooIf You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Diagnostics & Research Stocks
Thermo Fisher Scientific Inc.
$256.61B
DHRDanaher Corporation
$164.40B
NTRANatera, Inc.
$59.59B
IQVIQVIA Holdings Inc.
$45.53B
WATWaters Corporation
$44.92B
IDXXIDEXX Laboratories, Inc.
$43.60B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B














